Scholarly Index
Richard D. DiMarchi
Novo Nordisk (United States); 19,455 total citations; 245 total publications; best world rank #291
Novo Nordisk (United States)
19,455Total citations
245Total publications
72H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Diabetes Treatment and Management | Lifetime | 291 | US 120 | 98.86 |
| Pancreatic function and diabetes | Lifetime | 700 | US 296 | 98.10 |
| Regulation of Appetite and Obesity | Lifetime | 864 | US 378 | 95.55 |
| Pharmacology and Obesity Treatment | Lifetime | 814 | US 352 | 92.18 |
| Fibroblast Growth Factor Research | Lifetime | 842 | US 341 | 90.89 |
| Kruppel-like factors research | Lifetime | 627 | US 236 | 90.19 |
| Diabetes Treatment and Management | 2021-2025 | 342 | US 121 | 96.27 |
| Pancreatic function and diabetes | 2021-2025 | 669 | US 231 | 90.13 |
| Receptor Mechanisms and Signaling | 2021-2025 | 426 | US 155 | 87.52 |
| Neuropeptides and Animal Physiology | 2021-2025 | 915 | US 279 | 68.08 |